This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chan, C C Articles by Scarffe, J H Search for Related Content PubMed PubMed Citation Articles by Chan, C C Articles by Scarffe, J H

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1989 January; 33(1): 87-91

Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients.

Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom.

ABSTRACT

To assess the efficacy of ciprofloxacin in neutropenic patients, we conducted a randomized prospective trial comparing the combination of ciprofloxacin and netilmicin against piperacillin plus netilmicin as an empiric treatment of fever in cancer patients with neutropenia. Of 214 evaluable episodes, 115 and 99 were randomly assigned to the ciprofloxacin and the piperacillin arms, respectively. The overall response rates were very similar (59 and 62% for the ciprofloxacin and piperacillin arms, respectively). The response for the gram-positive bacteremias was almost identical (around 40%); this low response was due in part to an outbreak of infection by a multiply resistant strain of Staphylococcus epidermidis (for which the ciprofloxacin MIC was greater than or equal to 128 micrograms/ml) which occurred during the second half of the trial. Among gram-negative bacteremias, 9 of 11 infections (82%) responded to the ciprofloxacin combination compared with 3 of 7 (43%) that responded to the piperacillin combination (P = 0.23). The incidences of persistent, profound neutropenia were comparable in both treatments, but the susceptibility of the gram-negative organism to ciprofloxacin and netilmicin was significantly higher than was susceptibility to the other combination. Ciprofloxacin was well tolerated, and patients were able to convert from intravenous to oral therapy in 64 of 115 episodes.

This article has been cited by other articles:

• Peacock, J. E. Jr., Herrington, D. A., Wade, J. C., Lazarus, H. M., Reed, M. D., Sinclair, J. W., Haverstock, D. C., Kowalsky, S. F., Hurd, D. D., Cushing, D. A., Harman, C. P., Donowitz, G. R. (2002). Ciprofloxacin plus Piperacillin Compared with Tobramycin plus Piperacillin as Empirical Therapy in Febrile Neutropenic Patients: A Randomized, Double-Blind Trial. ANN INTERN MED 137: 77-87 [Abstract] [Full Text]  
• Giamarellou, H., Bassaris, H. P., Petrikkos, G., Busch, W., Voulgarelis, M., Antoniadou, A., Grouzi, E., Zoumbos, N. (2000). Monotherapy with Intravenous Followed by Oral High-Dose Ciprofloxacin versus Combination Therapy with Ceftazidime plus Amikacin as Initial Empiric Therapy for Granulocytopenic Patients with Fever. Antimicrob. Agents Chemother. 44: 3264-3271 [Abstract] [Full Text]  
• Marchbanks, C. R., Rowley, K. A. (1991). Update on Infections in the Immunocompromised Host. Journal of Pharmacy Practice 4: 282-294 [Abstract]